Nice to Know

In this section Cosmo will publish non-price sensitive news including information about upcoming events or announcements.

11/01/12 Country Representative European Business Awards 2011 - EBA Case Study

08/06/11 Full article from British Journal of Dermatology
Cortexolone 17α-propionate 1% cream, a new potent anti-androgen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study versus placebo and tretinoin (Retin-A® 0.05% cream) - (Trifu V, Tiplica GS, Naumescu E, Zalupca L, Moro L, Celasco G).

24/03/11 Abstract from British Journal of Dermatology
Cortexolone 17α-propionate 1% cream, a new potent anti-androgen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study versus placebo and tretinoin (Retin-A® 0.05% cream) - (Trifu V, Tiplica GS, Naumescu E, Zalupca L, Moro L, Celasco G).

13/12/10 Abstract from Antimicrob Agents Chemother
In vitro Activity and Single-Step Mutational Analysis of Rifamycin SV Tested Against Enteropathogens Associated With Travelers' Diarrhea and Clostridium Difficile (Farrell DJ, Putnam SD, Biedenbach DJ, Moro L, Bozzella R, Celasco G, Jones RN).

25/03/10 Santarus announces completion of enrollment in U.S. Phase III clinical study for Budesonide MMX

30/12/09 Santarus Submits IND For Phase III Clinical Testing Of Rifamycin SV MMX In Travelers' Diarrhea

03/06/09 Poster abstracts presented at the Digestive Disease Week (DDW)

• Colon-Release Parnaparin Sodium Tablets (CB-01-05 MMX®) for Active Left-sided Ulcerative Colitis: A Randomized, Double-Blind Controlled Study Versus Placebo.
  The poster was awarded a DDW Poster of Distinction
• Anti-Inflammatory and Immunomodulatory Activities of Parnaparin Sodium (CB-01-05)

05/05/2008 Inclusion of Cosmo in Swiss Performance Index (SPI)
Cosmo has received confirmation from SWX Swiss Exchange that the company's shares will be included in the Swiss Performance Index (SPI) as of 6 May, 2008. As of this day, the SPI will be open to all foreign domiciled companies that have a primary listing on SWX, subject to certain free-float.

04/10/2007 Market Making Agreement
In order to facilitate the daily trading of our shares on the SWX we have entered into a market making agreement with a well know bank that has a seat at the SWX.

25/04/2007 LIALDA™ (mesalamine)
LIALDA, the only once-daily oral formulation of mesalamine and approved by the FDA on January 16, 2007 became available to patients in the US on March 19, 2007.